⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NERV News
Minerva Neurosciences, Inc
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
globenewswire.com
NERV
Form 8-K
sec.gov
NERV
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
globenewswire.com
NERV
Form 8-K
sec.gov
NERV
Form 8-K
sec.gov
NERV
Minerva Announces Leadership Transition
globenewswire.com
NERV
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
globenewswire.com
NERV
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
globenewswire.com
NERV
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
globenewswire.com
NERV
Form 8-K
sec.gov
NERV